Pain News and Research

Latest Pain News and Research

Four percent annual growth for chronic pain drug market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the chronic pain drug market will experience modest four percent annual growth from 2008 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Although the market will increase over the next decade, generic erosion will constrain sales of key branded agents such as Johnson & Johnson's Topamax (topiramate) and Pfizer's Celebrex (celecoxib).

23 Sep 2009

NeuroTherm receives US patent for RF generator

NeuroTherm is pleased to be recognized by the United States Patent Office as the first company worldwide to develop and release a multiple output radiofrequency generator used in the treatment of chronic pain, ref. US Patent No. 7,574,257.

23 Sep 2009

NASDAQ halts trading in CombinatoRx's common stock

CombinatoRx, Incorporated (NASDAQ: CRXX) announced that NASDAQ has halted trading in the Company’s common stock today.

23 Sep 2009

Bioelectronics files for pre-marketing clearance for its ActiPatch® Therapy products

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced that it filed today with the U.S. Government's Food and Drug Administration for 510(K) pre-marketing clearance for its ActiPatch® Therapy products.

23 Sep 2009

Researchers make significant advances in the treatment of metastatic malignant melanoma

Researchers have made significant advances in the treatment of metastatic malignant melanoma - one of the most difficult cancers to treat successfully once it has started to spread - according to a study to be presented at Europe's largest cancer congress, ECCO 15 - ESMO 34, in Berlin on Thursday.

23 Sep 2009

Ambassador Nancy G. Brinker calls for a global fight against cancer

The leader of the global breast cancer movement today warned of a coming wave of cancer deaths and told global health ministers to be “fearless and united” in addressing the growing cancer crisis, particularly in developing countries.

23 Sep 2009

Phase 1 extension study results of Plexxikon's PLX4032 in metastatic melanoma patients encouraging

Plexxikon Inc. today announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors.

23 Sep 2009

Advancements in the treatment of metastatic malignant melanoma

23 Sep 2009

NIST collaborates with private industry to release a new reference material for beryllium

Researchers at the National Institute of Standards and Technology (NIST), in collaboration with private industry and other government agencies, have produced a new reference material for beryllium. Beryllium, an exotic rare-earth metal used as a hardener in high-performance alloys and ceramics, can cause berylliosis-a chronic, incurable and sometimes fatal illness.

23 Sep 2009

ESMO recognises 27 cancer centers for their excellent palliative care

The European Society for Medical Oncology is proud to announce that it has formally recognized 27 cancer centers for their commitment to providing excellent palliative care as part of the care they offer to patients.

23 Sep 2009

Preventing nerve cell death in diabetics

Dennis Paul, PhD, Associate Professor of Pharmacology, and Harry Gould, MD, PhD, the Tom Benson Professor of Neurology at LSU Health Sciences Center New Orleans, have been awarded one of two scientific research grants made in 2009 by The Neuropathy Association. The $80,000 grant will fund research to learn how to prevent nerve cell death in people with uncontrolled or untreated diabetes resulting in neuropathy.

23 Sep 2009

FDA committees to review Neuromed’s NDA for Exalgo

CombinatoRx, Incorporated (NASDAQ: CRXX) and Neuromed Pharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the September 23, 2009 joint meeting of its Anesthetics and Life Support Advisory Committee and its Drug Safety and Risk Management Advisory Committee.

23 Sep 2009

Results of OASIS clinical trial reported by Cardiovascular Systems

Two-year follow-up of patients in the first-ever prospective, multi-center clinical trial evaluating a plaque removal product show promising results after treatment with the Diamondback 360® PAD System, a minimally invasive catheter system that removes hardened plaque to restore blood flow in arteries.

23 Sep 2009

Decision Points helps patients with important medical decisions

Healthwise has released a new, interactive generation of its Decision Points to help people make better decisions with their doctors.

23 Sep 2009

CIGNA announces initial results of its multi-year strategy to improve customer's experience

CIGNA (NYSE:CI) today announced the initial results of its multi-year strategy that places an entirely new focus on improving customers’ experience. The effort has led to an improvement in customer understanding of their benefits in excess of 100 percent, a 50 percent reduction in the number of printed materials customers receive, and the use of simpler language that doesn’t rely on insurance jargon. It also led CIGNA to become the first in its industry to offer 24 hour-a-day, seven day-a-week customer service.

23 Sep 2009

Alpha Orthotics announces launch of its Medial Mid-foot Brace in the U.S.

Splayfoot, also called "fallen arch" occurs when the arch of the foot collapses, with the entire sole of the foot coming into complete or near-complete contact with the ground. An estimated 20%-30% of Americans have this condition where the arch never develops, or collapses in one or both feet.

23 Sep 2009

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.

22 Sep 2009

Beech Sandal Company supports breast cancer awareness program

Beech Sandal Company declares its commitment to raising awareness and funding for education, research and treatment for women's health issues by donating its popular, health-oriented Yoga Sandals(R) footwear and a portion of the company's sales to support a number of worthy causes.

22 Sep 2009

Event to address rheumatoid arthritis

26 men and women with RA from across europe honoured as they share their inspirational stories. Actress, artist and activist Jane Seymour will host the first My Day for RA European event in Barcelona, Spain this evening to recognise the daily challenges, hopes and achievements of people living with rheumatoid arthritis (RA).

22 Sep 2009

Drug registration process for Nutra Pharma's pain reliever begins

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Canada and Europe for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

22 Sep 2009